Published in Dermatol Ther (Heidelb) on February 01, 2017
The role of cyclooxygenases in inflammation, cancer, and development. Oncogene (1999) 5.50
The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis (2009) 5.01
Regulation of immune responses by prostaglandin E2. J Immunol (2012) 3.93
Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res (1995) 2.74
Long-term (6 and 12 months) follow-up of two prospective, randomized, controlled phase III trials of photodynamic therapy with BF-200 ALA and methyl aminolaevulinate for the treatment of actinic keratosis. Br J Dermatol (2013) 2.70
COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis (1998) 2.30
Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity. Cell (2015) 2.10
Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition. Carcinogenesis (1999) 2.08
Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcinog (1999) 1.95
Gene expression patterns of normal human skin, actinic keratosis, and squamous cell carcinoma: a spectrum of disease progression. Arch Dermatol (2010) 1.78
A double-blind, vehicle-controlled study evaluating masoprocol cream in the treatment of actinic keratoses on the head and neck. J Am Acad Dermatol (1991) 1.75
Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a multicentre, randomized, observer-blind phase III study in comparison with a registered methyl-5-aminolaevulinate cream and placebo. Br J Dermatol (2011) 1.75
Nonsteroidal anti-inflammatory drugs and the risk of skin cancer: a population-based case-control study. Cancer (2012) 1.74
Cyclooxygenases in cancer: progress and perspective. Cancer Lett (2004) 1.74
Arachidonic acid is preferentially metabolized by cyclooxygenase-2 to prostacyclin and prostaglandin E2. J Biol Chem (1999) 1.65
The risk of progression to invasive disease. J Am Acad Dermatol (2000) 1.59
Guidelines for the management of actinic keratoses. Br J Dermatol (2007) 1.49
Pharmacoeconomic considerations in treating actinic keratosis. Pharmacoeconomics (2009) 1.24
Cyclooxygenase-2 expression is critical for chronic UV-induced murine skin carcinogenesis. Mol Carcinog (2007) 1.24
A role for cyclooxygenase-2 in ultraviolet light-induced skin carcinogenesis. Mol Carcinog (2007) 1.15
Overexpression of the prostaglandin E2 receptor EP2 results in enhanced skin tumor development. Oncogene (2006) 1.13
Importance of the EP(1) receptor in cutaneous UVB-induced inflammation and tumor development. J Invest Dermatol (2006) 1.12
Interventions for actinic keratoses. Cochrane Database Syst Rev (2012) 1.10
Molecular mechanisms of mouse skin tumor promotion. Cancers (Basel) (2010) 1.09
Nonsteroidal anti-inflammatory drugs and the risk of actinic keratoses and squamous cell cancers of the skin. J Am Acad Dermatol (2005) 1.06
Effect of NSAIDs on the recurrence of nonmelanoma skin cancer. Int J Cancer (2006) 1.03
Association between nonsteroidal anti-inflammatory drug use and cutaneous squamous cell carcinoma. Arch Dermatol (2010) 1.03
Cyclooxygenase-dependent signaling is causally linked to non-melanoma skin carcinogenesis: pharmacological, genetic, and clinical evidence. Cancer Metastasis Rev (2011) 0.97
Actinic keratosis treatment as a key component of preventive strategies for nonmelanoma skin cancer. J Clin Aesthet Dermatol (2010) 0.96
Three percent diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses: a meta-analysis of the recent studies. Arch Dermatol Res (2005) 0.95
Cyclooxygenase-2 inhibition suppresses alphavbeta6 integrin-dependent oral squamous carcinoma invasion. Cancer Res (2006) 0.95
Evidence- and consensus-based (S3) Guidelines for the Treatment of Actinic Keratosis - International League of Dermatological Societies in cooperation with the European Dermatology Forum - Short version. J Eur Acad Dermatol Venereol (2015) 0.95
Actinic keratosis with atypical basal cells (AK I) is the most common lesion associated with invasive squamous cell carcinoma of the skin. J Eur Acad Dermatol Venereol (2014) 0.94
The chemopreventive efficacies of nonsteroidal anti-inflammatory drugs: the relationship of short-term biomarkers to long-term skin tumor outcome. Cancer Prev Res (Phila) (2013) 0.92
Daylight photodynamic therapy with methyl aminolevulinate cream as a convenient, similarly effective, nearly painless alternative to conventional photodynamic therapy in actinic keratosis treatment: a randomized controlled trial. Br J Dermatol (2014) 0.91
Treatment of actinic keratoses with sequential combination of 5-fluorouracil and photodynamic therapy. J Drugs Dermatol (2005) 0.89
Diclofenac sodium 3% gel in the treatment of actinic keratoses postcryosurgery. J Drugs Dermatol (2008) 0.89
MiR-26a and miR-144 inhibit proliferation and metastasis of esophageal squamous cell cancer by inhibiting cyclooxygenase-2. Oncotarget (2016) 0.89
Treatment of actinic keratoses with sequential use of photodynamic therapy; and imiquimod 5% cream. J Drugs Dermatol (2009) 0.88
Low-dose 5-fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results. Br J Dermatol (2011) 0.88
Cyclooxygenase-2 promotes tumor growth and suppresses tumor immunity. Cancer Cell Int (2015) 0.86
Enhanced death ligand-induced apoptosis in cutaneous SCC cells by treatment with diclofenac/hyaluronic acid correlates with downregulation of c-FLIP. J Invest Dermatol (2010) 0.86
Aspirin and nonsteroidal anti-inflammatory drugs can prevent cutaneous squamous cell carcinoma: a systematic review and meta-analysis. J Invest Dermatol (2014) 0.86
Combined Treatments with Photodynamic Therapy for Non-Melanoma Skin Cancer. Int J Mol Sci (2015) 0.86
Recurrence rates and patient assessed outcomes of 0.5% 5-fluorouracil in combination with salicylic acid treating actinic keratoses. Eur J Dermatol (2012) 0.84
Topical diclofenac 3% gel plus cryotherapy for treatment of multiple and recurrent actinic keratoses. Clin Exp Dermatol (2008) 0.83
European Dermatology Forum Guidelines on topical photodynamic therapy. Eur J Dermatol (2015) 0.81
Treatment of actinic keratoses on the dorsum of the hands: ALA-PDT versus diclofenac 3% gel followed by ALA-PDT. A placebo-controlled, double-blind, pilot study. J Dermatolog Treat (2009) 0.80
The expression of p53 and COX-2 in basal cell carcinoma, squamous cell carcinoma and actinic keratosis cases. Turk Patoloji Derg (2012) 0.79
The tumor promoting activity of the EP4 receptor for prostaglandin E2 in murine skin. Mol Oncol (2014) 0.79
Daylight photodynamic therapy with methyl aminolevulinate cream is effective and nearly painless in treating actinic keratoses: a randomised, investigator-blinded, controlled, phase III study throughout Europe. J Eur Acad Dermatol Venereol (2015) 0.77
Sequential treatment of multiple actinic keratoses with solaraze and actikerall. Case Rep Dermatol (2014) 0.76